Investors & Media

Transformative science, targeted medicines

We are working to advanceĀ a deep pipeline of precision therapies, designed to allow patients to live longer, better lives. Our approach combines world-leading expertise in protein kinases with sound execution and an intense focus on discovery.

SEC filing details

Document Details

Form
Filing Date
Mar 17, 2021
Document Date
Mar 3, 2021
Form Description
Amendment to a previously filed 4
Filing Group
3,4,5
Company
Blueprint Medicines Corp.
Issuer
Blueprint Medicines Corp
Filer
Hurley Ariel